The Group's R&D team is led by Dr. Su Hongsheng, a leading biopharmaceutical talent returning from studying abroad, and consists of two R&D centers in Beijing (Beijing Gensciences Inc.) and Zhengzhou (Zhengzhou Gensciences Inc.). It has so far developed into a first-class biopharmaceutical R&D team in China with about 150 members, and more than half have postgraduate degrees or above with extensive and professional experience in innovative biological macromolecule drug development.

Based on clinical needs and oriented by clinical advantages, the R&D team achieves the development goals of “high efficiency, high safety and high success rate” by a “pooled” innovation approach. Making a breakthrough in the treatment of the rare disease “hemophilia”, the team is expected to fill the gaps in the domestic industry and provide safer and more effective solutions for Chinese hemophiliacs to help them "return to normal life", improve the quality of life, and reduce the burden on their families and the society.

In the development of long-acting coagulation factor products, the R&D team has overcome a number of industry-recognized top technological barriers represented by “coagulation factor VIII” and “activated coagulation factor VII”, set up an efficient biomacromolecule drug development team, and constructed a mature and sound bio-innovative drug development system and numerous unique technological platforms, satisfying the needs for the development of a wide range of expression systems such as cell culture and microbial fermentation. A variety of long-acting technical routes, such as fusion proteins and protein modifications, have greatly reduced the cycle and cost of innovation transformation, and are expected to expand from rare diseases in the field of coagulation to a wider range of serious diseases and chronic disease indications such as anti-tumor and metabolic diseases in the near future.